May 15th 2024
Novo Holdings is expected to acquire 60% of Single Use Support, with the remaining shares being held by Danaher and the company founders.
Pharm Exec's 16th Annual Industry Audit
September 22nd 2017With our latest review indicating declines in shareholder value and shareholder value to sales, those companies that score well in critical profit management metrics such as return on invested capital are best positioned to maintain that crucial edge in performance execution.
Pharma and Biotech Markets: Challenges and Opportunities
January 18th 2017With the soaring valuations of companies in the public and M&A markets now seemingly a distant memory, the challenge for pharma and biotech business will be choosing just the right overall mix of M&A, licensing, and partnering.